Lv62
2400 积分 2026-01-18 加入
Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer
16天前
已完结
Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer
16天前
已完结
Calibrating Models in Economic Evaluation
21天前
已完结
Calibrating Models in Economic Evaluation
21天前
已完结
Cost-effectiveness analysis of human–AI collaboration in disease screening
21天前
已完结
Survival Extrapolation Incorporating General Population Mortality Using Excess Hazard and Cure Models: A Tutorial
22天前
已完结
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial
24天前
已完结
皖公网安备34019202002308
